Frequency and severity of alopecia for selected chemotherapy agents and combinations

Severe	Moderate	Mild
Frequent
Combination chemotherapy containing doxorubicin, docetaxel, paclitaxel, etoposide Cyclophosphamide (IV at doses >300 mg/m²) Daunorubicin Docetaxel Doxorubicin (>40 mg/m²) Epirubicin (>30 mg/m²) Eribulin Etoposide (IV) Ifosfamide Irinotecan (high dose, every 3 weeks) Ixabepilone Paclitaxel (every 2 to 3 weeks)	Carboplatin (AUC 5 to 6) Mechlorethamine Methotrexate Paclitaxel (weekly)	Bleomycin Irinotecan (low dose, weekly)
Infrequent
Enfortumab vedotin Etoposide (oral) Sacituzumab govitecan	Cyclophosphamide (oral) Fam-trastuzumab deruxtecan Oxaliplatin Vinblastine Vincristine Vinorelbine	Capecitabine Carboplatin (weekly) Cisplatin Fluorouracil Hydroxyurea Thiotepa Trastuzumab deruxtecan

IV: intravenous; AUC: area under the curve.

Data from:

Rugo HS, Klein P, Melin SA, et al. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA 2017; 317:606.
Nangia J, Wang T, Osborne C, et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA 2017; 317:596.
Batchelor D. Hair and cancer chemotherapy: consequences and nursing care--a literature study. Eur J Cancer Care (Engl) 2001; 10:147.
Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.
Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol 2012; 67:e37.

Graphic 112007 Version 3.0